DelveInsight’s “Warm Autoimmune hemolytic anemia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Warm Autoimmune hemolytic anemia, historical and forecasted epidemiology as well as the Warm Autoimmune hemolytic anemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Warm Autoimmune hemolytic anemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Warm Autoimmune hemolytic anemia Market Forecast
Some of the key facts of the Warm Autoimmune hemolytic anemia Market Report:
-
The Warm Autoimmune hemolytic anemia market size was valued approximately USD 545 Million in the year 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In February 2024, Novartis declared its intention to initiate a voluntary public takeover bid to acquire MorphoSys through an agreement.
-
In September 2023, Zenas BioPharma has forged a license and collaboration deal with Bristol Myers Squibb to jointly develop and market obexelimab for autoimmune conditions in specific Asian and Oceanian regions, including Japan, South Korea, Taiwan, Singapore, Hong Kong, and Australia.
-
McCrae (2022) estimated that between 30,000 to 49,000 individuals in the United States are thought to be impacted by warm autoimmune hemolytic anemia (wAIHA).
-
In the United States, the highest prevalence of cases was observed in individuals aged 65 and older, while the lowest cases were reported in the age group of 0-24 years in 2023.
-
In the EU4 nations, Germany recorded the highest count of diagnosed prevalent cases of warm autoimmune hemolytic anemia (wAIHA), totaling nearly 9,000 cases, while Spain reported the lowest number of cases in 2023.
-
Key Warm Autoimmune hemolytic anemia Companies: Rigel Pharmaceuticals, Incyte Corporation, Sanofi, Johnson & Johnson, Janssen Research & Development, Annexon, Inc., Apellis Pharmaceuticals, Inc., Rigel Pharmaceuticals, Hutchison Medipharma Limited, and others
-
Key Warm Autoimmune hemolytic anemia Therapies: Fostamatinib, Parsaclisib, Rilzabrutinib, Nipocalimab, M281, ANX005, APL-2, Fostamatinib disodium, HMPL-523(300mg PO QD), and others
-
The Warm Autoimmune hemolytic anemia epidemiology based on gender analyzed that in case of Warm Autoimmune hemolytic anemia, gender ratio revealed preponderance of the female gender over the male counterpart
-
The Warm Autoimmune hemolytic anemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Warm Autoimmune hemolytic anemia pipeline products will significantly revolutionize the Warm Autoimmune hemolytic anemia market dynamics.
Warm Autoimmune hemolytic anemia Overview
Warm autoimmune hemolytic anemia (AIHA) is a type of autoimmune disorder characterized by the destruction of red blood cells (hemolysis) by the body's immune system. In warm AIHA, the immune system produces antibodies that mistakenly target the body's own red blood cells, leading to their premature destruction. This process occurs predominantly at body temperature (hence the term "warm") and typically involves the destruction of red blood cells in the spleen.
Get a Free sample for the Warm Autoimmune hemolytic anemia Market Report:
https://www.delveinsight.com/report-store/warm-autoimmune-hemolytic-anemia-waiha-market
Warm Autoimmune hemolytic anemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Warm Autoimmune hemolytic anemia Epidemiology Segmentation:
The Warm Autoimmune hemolytic anemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Warm Autoimmune hemolytic anemia
-
Prevalent Cases of Warm Autoimmune hemolytic anemia by severity
-
Gender-specific Prevalence of Warm Autoimmune hemolytic anemia
-
Diagnosed Cases of Episodic and Chronic Warm Autoimmune hemolytic anemia
Download the report to understand which factors are driving Warm Autoimmune hemolytic anemia epidemiology trends @ Warm Autoimmune hemolytic anemia Epidemiology Forecast
Warm Autoimmune hemolytic anemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Warm Autoimmune hemolytic anemia market or expected to get launched during the study period. The analysis covers Warm Autoimmune hemolytic anemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Warm Autoimmune hemolytic anemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Warm Autoimmune hemolytic anemia Therapies and Key Companies
-
Fostamatinib: Rigel Pharmaceuticals
-
Parsaclisib: Incyte Corporation
-
Rilzabrutinib: Sanofi
-
Nipocalimab: Johnson & Johnson
-
M281: Janssen Research & Development
-
ANX005: Annexon, Inc.
-
APL-2: Apellis Pharmaceuticals, Inc.
-
Fostamatinib disodium: Rigel Pharmaceuticals
-
HMPL-523(300mg PO QD): Hutchison Medipharma Limited
Discover more about therapies set to grab major Warm Autoimmune hemolytic anemia market share @ Warm Autoimmune hemolytic anemia Treatment Market
Warm Autoimmune hemolytic anemia Market Drivers
-
Increasing patient population
-
Advancement in research and development
-
Improved clinical trials
-
Patient assistance programs
-
New therapeutic agents
Warm Autoimmune hemolytic anemia Market Barriers
-
Increasing refractory cases
-
Associated co-morbidities
-
Unavailability of better treatment options
-
Therapy failure
-
Lack of disease understanding
-
Unavailability of curative treatment
Scope of the Warm Autoimmune hemolytic anemia Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Warm Autoimmune hemolytic anemia Companies: Rigel Pharmaceuticals, Incyte Corporation, Sanofi, Johnson & Johnson, Janssen Research & Development, Annexon, Inc., Apellis Pharmaceuticals, Inc., Rigel Pharmaceuticals, Hutchison Medipharma Limited, and others
-
Key Warm Autoimmune hemolytic anemia Therapies: Fostamatinib, Parsaclisib, Rilzabrutinib, Nipocalimab, M281, ANX005, APL-2, Fostamatinib disodium, HMPL-523(300mg PO QD), and others
-
Warm Autoimmune hemolytic anemia Therapeutic Assessment: Warm Autoimmune hemolytic anemia current marketed and Warm Autoimmune hemolytic anemia emerging therapies
-
Warm Autoimmune hemolytic anemia Market Dynamics: Warm Autoimmune hemolytic anemia market drivers and Warm Autoimmune hemolytic anemia market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Warm Autoimmune hemolytic anemia Unmet Needs, KOL’s views, Analyst’s views, Warm Autoimmune hemolytic anemia Market Access and Reimbursement
To know more about Warm Autoimmune hemolytic anemia companies working in the treatment market, visit @ Warm Autoimmune hemolytic anemia Clinical Trials and Therapeutic Assessment
Table of Contents
1. Warm Autoimmune hemolytic anemia Market Report Introduction
2. Executive Summary for Warm Autoimmune hemolytic anemia
3. SWOT analysis of Warm Autoimmune hemolytic anemia
4. Warm Autoimmune hemolytic anemia Patient Share (%) Overview at a Glance
5. Warm Autoimmune hemolytic anemia Market Overview at a Glance
6. Warm Autoimmune hemolytic anemia Disease Background and Overview
7. Warm Autoimmune hemolytic anemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Warm Autoimmune hemolytic anemia
9. Warm Autoimmune hemolytic anemia Current Treatment and Medical Practices
10. Warm Autoimmune hemolytic anemia Unmet Needs
11. Warm Autoimmune hemolytic anemia Emerging Therapies
12. Warm Autoimmune hemolytic anemia Market Outlook
13. Country-Wise Warm Autoimmune hemolytic anemia Market Analysis (2020–2034)
14. Warm Autoimmune hemolytic anemia Market Access and Reimbursement of Therapies
15. Warm Autoimmune hemolytic anemia Market Drivers
16. Warm Autoimmune hemolytic anemia Market Barriers
17. Warm Autoimmune hemolytic anemia Appendix
18. Warm Autoimmune hemolytic anemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
